Glaukos Corporation

State of Alaska Department of Revenue Sells 9,393 Shares of Glaukos Corporation $GKOS

Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?

GKOS shares surge 36.8% in six months, fueled by strong sales, iDose TR and Epioxa expansion, higher guidance and promising clinical developments.

Glaukos: The Second J-Code Rewrites The Risk Math

Glaukos is transitioning from a single-product reimbursement story to a diversified ophthalmic pharmaceutical platform with two J-coded drugs and strong operating leverage. Q2 net sales grew 50% YoY to $185.6M, driven by iDose TR and the Epioxa launch, with non-GAAP gross margin reaching 85% and breakeven P&L. Management raised 2026 net sales guidance to $680–700M, with iDose TR sales expected at $275–280M and corneal health growth of 20%+.

Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal

GKOS expands its retinal pipeline with a licensing deal for RO-104 and exclusive RevMod platform rights, even as shares decline 6.3% following the news.

Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy

Ophthalmic pharmaceutical and medical technology firm Glaukos Corporation (NYSE:GKOS) reported successful topline outcomes from its latest Phase 4 clinical study.

Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced positive topline results from the Phase 4 prospective, randomized, controlled clinical trial (GLK-101-04) evaluating iDose® TR administered in conjunction with cataract surgery compared to cataract surgery alone in patients with open-angle glaucoma (OA.

Glaukos Advances Eye Care Portfolio with Three-Year Epioxa Trial Data and Licensing Deal

Glaukos Corporation (NYSE:GKOS) reported three-year trial results for its non-invasive keratoconus treatment while simultaneously securing an exclusive licensing deal to broaden its pipeline of retinal disease therapies.

Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced an exclusive license agreement with RevOpsis Therapeutics, Inc. to develop and commercialize RO-104, a novel tri-specific biologic for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macula edema (DME), diabetic retinopat.